Global Metabolomics Market - 2022-2029

Market Overview

Metabolomics Market was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 11.2% during the forecast period (2022-2029).

In metabolomics, biological metabolites are identified and quantified using sophisticated analytical techniques, and information is extracted and interpreted using statistical and multivariate approaches. LC-MS/MS, GC-MS, and/or NMR are some of the complimentary analytical techniques used in metabolomics to identify and quantify as many known and unidentified metabolites as possible.

Market Dynamics

The metabolomics market growth is driven by the rising funding in research and development, rising adoption of targeted therapies, technological advamcement, increasing healthcare and R&D expenditure, rise in adoption of technology for clinical applications.

The rising funding for reserch and development is expected to drive the market growth

The rising funding for research and development from private and government organizations is expected to boost the market over the forecast period. For instance, the Canadian Foundation for Innovation's Major Science Initiatives Fund has provided $8,879,183 to The Metabolomics Innovation Centre (TMIC) and $10,684,968 to GlycoNet Integrated Services (GIS), helping these centers to continue their pioneering research, including glycomics and metabolomics.

In addition, the market players are adopting market strategies, including acquisition, collaboration and product launches. For instance, in 2020, Danaher Corporation acquired GE Healthcare's Life Sciences business. Also, In 2020, Agilent and Thermo Fisher extended their agreement to enhance the compatibility of Thermo Fisher's analytical systems with Agilent's OpenLAb Chromatography Data System.

In 2020, Waters Corporation announced the opening of Immerse Cambridge, a research facility in the center of Kendall Square in Cambridge. The community's strategic, collaborative venue, Immerse Cambridge, will allow Waters to work with academia and research to accelerate the next round of scientific discoveries. Also, in 2020, Hitachi acquired the remaining shares of Hitachi High-Technologies billion and made it is subsidiary. This subsidiary will be responsible for manufacturing measuring and analytical equipment, along with developing chipmaking equipment and industrial materials and systems.

The complexity of the data will hamper the growth of the market

However, no one analytical method can be used to analyze the full metabolome due to the chemical diversity of small molecule metabolites. Therefore, there is an increased demand for physical storage, accurate and thorough analysis, and appropriate software/databases for visualization. The resulting data is also more complicated. Therefore, it is anticipated that the complexity of the data produced during life science research and the challenges associated with handling it will restrain the development of the metabolomics market.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global metabolomics market. As per the article published in Scientific Reports in January 2022, While some metabolomics studies have used nuclear magnetic resonance (NMR), mass spectrometry (MS)-based metabolomics has been the method of choice for identifying prospective diagnostic biomarker candidates in COVID-19 disease. Metabolomics has been used to address various topics related to COVID-19 disease. For example, metabolomics has shown sex-specific metabolic shifts in non-severe COVID-19 patients during recovery, demonstrating that the major plasma metabolic changes were fatty acids in men and glycerophosphocholines and carbohydrates in men and women. As demonstrated by metabolomics, plasma metabolite profiles of COVID-19 survivors with impaired pulmonary function may be distinguished from those of healthy donors or those with normal pulmonary function.

In addition, the key players are engaged in research activities during the pandemic. For instance, in December 2020, The FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel, developed by Bruker Corporation, allows for the sensitive and simultaneous detection of the SARS-CoV-2 virus, influenza viruses A and B, as well as the respiratory syncytial virus (RSV)

Also, in July 2020, The FluoroType SARS-CoV-2 plus next-generation 6-plex PCR assay was introduced by Bruker Corporation to precisely identify the SARS-CoV-2 virus, which is responsible for the respiratory and systemic illness COVID-19.

Segment Analysis

The separation technique segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The separation technique segment is expected to boost the market throughout the forecast. As per the article published in Novel Approaches in Drug Designing & Development in August 2021, the analytical technique of liquid chromatography is used to isolate the target analyte from the mixture. To effectively separate molecules of interest, liquid chromatography uses a liquid as the mobile phase and a solid as the stationary phase. Mass spectroscopy is performed to determine the molecular mass of the sample of interest. By measuring the sample ion's mass to charge ratio, the molecule's mass is ascertained. Due to its selectivity, low sample volume requirements, sensitivity, and speed, the combination of liquid chromatography and mass spectrometry (LC-MS) is a potent instrument with several applications. LC is now compatible with MS due to creative and fruitful research over the past few years on constructing a potential interface link between the two. In the preclinical development stage, LC-MS detects impurities, degradants, and metabolites. In addition, the use of LC-MS/MS for protein quantification has attracted much attention. It is employed in the detection of biomarkers.

Geographical Analysis

North America region holds the largest market share of the global Metabolomics market

North America dominates the metabolomics market and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to government initiatives, growth and development research activities in metabolomics, and an increase in the adoption of metabolomics in precision medicine.

The primary aim of the Metabolomics Association of North America (MANA) is to advance the field of metabolomics, particularly in North America; to give North American researchers in metabolomics sciences and related fields the chance to network; to facilitate connections between academia and industry; to provide venues for the presentation of research findings and for workshops, and to encourage the publication of metabolomics research.

In addition, in April 2020, Gilead Sciences, Inc., and Second Genome, entered into a four-year strategic collaboration to find potential new targets and drug candidates for the treatment of inflammatory bowel disease as well as to identify biomarkers linked to clinical response in up to five of Gilead's pipeline compounds for the treatment of fibrosis, inflammation, and other diseases (IBD).

Competitive Landscape

The metabolomics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Agilent Technologies Inc., Danaher Corporation, Waters Corporation, Bruker Corporation, Human Metabolome Technologies, Inc., Metabolon Inc., LECO Corporation, and Shimadzu Corporation among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, contributing to the growth of the global metabolomics market.

For instance,

• In June 2021, Bruker Corporation launched the FluoroType SARS-CoV-2 varied Q assay, a quantitative Liquid Array mid-plexPCR panel. This novel assay panel also detects several important mutations, enabling laboratories and hospitals to differentiate many major viral variants routinely on all positive samples. The assay achieved a sensitivity of 98% and a specificity of 100% during its clinical performance evaluation study.
• In June 2021, at Bruker's virtual 4D-Proteomics eXceed Symposium (eXceed Symposia 2021 | Bruker), Bruker Corporation launched the two new Tim stop instruments. In addition, they advance and enable new applications and methods in unbiased proteomics/PTM characterization and unbiased, deep multi-omic biomarker discovery, for example, in cancer liquid biopsy research.

Thermo Fisher Scientific Inc

Overview:

Thermo Fisher Scientific Inc. is an American company founded in 1956 and headquartered in the United States. It provides solutions including chromatographic separations such as GC, LC and IC. It produces novel, stringent and reproducible results for high-impact discoveries.

Treatment type Portfolio:

Orbitrap Exploris GC 240: Thermo Scientific Orbitrap Exploris GC 240 mass spectrometer facilitates the most difficult analytical challenges. It delivers uncompromising qualitative and quantitative information and provides the need for research laboratories for compound identification and quantitation, including discovery profiling, metabolomics, industry research and applied quantification analyses, to gain unparalleled access to information-rich data with ease.

The global metabolomics market report would provide access to approximately 60+ market data tables, 55+ figures, and in the range of 200+ (approximate) pages.